Urothelial Cancer: One Step Forward to Understand How to Combine and Sequence Treatments Against Novel Targets

The THOR study, presented at ESMO 2023 by Dr. Arlene Siefker-Radtke from the MD Anderson Cancer Center in the USA, investigates the comparative effectiveness of erdafitinib and pembrolizumab in the context of metastatic urothelial carcinoma.
This particular cohort of the THOR trial was dedicated to exploring the potential advantages for patients with PD-L1 low tumors, with the aim of gaining insights into the impact of treatment sequencing.